Skip to main content

Table 2 Short-term lipid profile alteration among statin plus evolocumab/statin/statin plus ezetimibe lipid-lowering strategies in AMI patients after PSM adjustment

From: In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

 

Statin

Statin+

Ezetimibe

Statin+

Evolocumab

p1

p2

LDL (mmol/L)

Admission

3.11 ± 1.02

3.24 ± 1.13

3.24 ± 0.98

0.303

0.968

Follow-up(1 m)

1.58 ± 0.44

1.96 ± 0.82

0.92 ± 0.62

< 0.001

< 0.001

Follow-up(3 m)

1.61 ± 0.49

2.10 ± 0.82

1.17 ± 0.73

0.048

< 0.001

TG (mmol/L)

Admission

1.56 ± 1.01

1.55 ± 0.72

1.57 ± 0.74

0.927

0.823

Follow-up(1 m)

1.33 ± 0.67

1.53 ± 0.70

1.29 ± 0.65

0.121

0.038

Follow-up(3 m)

1.57 ± 1.13

1.66 ± 0.84

1.18 ± 0.51

0.214

0.011

HDL (mmol/L)

Admission

0.98 ± 0.22

1.02 ± 0.22

0.99 ± 0.21

0.593

0.364

Follow-up(1 m)

1.01 ± 0.22

1.05 ± 0.25

1.03 ± 0.24

0.042

0.654

Follow-up(3 m)

1.00 ± 0.18

1.00 ± 0.25

1.14 ± 0.32

0.145

0.078

ApoA (g/L)

Admission

1.08 ± 0.20

1.11 ± 0.20

1.09 ± 0.17

0.785

0.240

Follow-up(1 m)

1.17 ± 0.18

1.18 ± 0.18

1.21 ± 0.19

0.223

0.390

Follow-up(3 m)

1.20 ± 0.17

1.15 ± 0.20

1.25 ± 0.24

0.525

0.122

ApoB

(g/L)

Admission

0.99 ± 0.21

1.00 ± 0.26

1.00 ± 0.23

0.676

0.974

Follow-up(1 m)

0.64 ± 0.16

0.70 ± 0.22

0.39 ± 0.20

< 0.001

< 0.001

Follow-up(3 m)

0.59 ± 0.15

0.75 ± 0.22

0.46 ± 0.20

0.038

< 0.001

ApoE (mg/L)

Admission

41.83 ± 18.16

41.60 ± 16.61

41.96 ± 12.92

0.950

0.853

Follow-up(1 m)

33.82 ± 11.29

34.46 ± 11.93

20.79 ± 9.39

< 0.001

< 0.001

Follow-up(3 m)

32.83 ± 10.80

30.44 ± 9.50

21.59 ± 8.18

0.018

0.013

LP(a) (mg/L)

Admission

331.77

310.66

330.55

0.975

0.679

Follow-up(1 m)

281.96

283.66

271.18

0.902

0.876

Follow-up(3 m)

358.29

370.88

345.92

0.951

0.867

TCDL (mmol/L)

Admission

4.97 ± 1.19

5.03 ± 1.30

5.00 ± 1.16

0.799

0.884

Follow-up(1 m)

3.16 ± 0.58

3.57 ± 0.90

2.37 ± 0.74

< 0.001

< 0.001

Follow-up(3 m)

3.18 ± 0.56

3.72 ± 1.02

2.79 ± 0.72

0.074

< 0.001

  1. Data are shown as the mean ± SD, median or n (%). p1, Statin plus evolocumab vs. statin; p2, Statin plus evolocumab vs. statin plus ezetimibe. For statistical analysis, one-way ANOVA followed by Sidak’s multiple comparison test was applied
  2. TG Triglyceride, LDL Low-density lipoprotein, HDL High-density lipoprotein, ApoA Apolipoprotein A, ApoB Apolipoprotein B, ApoE Apolipoprotein E, TCDL Total cholesterol lipoprotein, Lp(a) Lipoprotein(a)